ConductScience.org, home

Paper22944331

Prediction and monitoring of treatment effect using T1-weighted dynamic contrast-enhanced magnetic resonance imaging in colorectal liver metastases: potential of whole tumour ROI and selective ROI analysis.

Coenegrachts K and 3 others. Eur J Radiol, 2012. Cited by 26 papers, by iCite.

Cite this record

ConductScience Library. Prediction and monitoring of treatment effect using T1-weighted dynamic contrast-enhanced magnetic resonance imaging in colorectal liver metastases: potential of whole tumour ROI and selective ROI analysis. Papers, record 22944331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22944331

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Prediction and monitoring of treatment effect using T1-weighted dynamic contrast-enhanced magnetic resonance imaging in colorectal liver metastases: potential of whole tumour ROI and selective ROI analysis.
PubMed
Journal
Eur J Radiol
PubMed
Year
2012
PubMed
Publication types
Clinical Trial, Journal Article
PubMed
Citations, by iCite
26
iCite
Relative citation ratio, by iCite
0.92
iCite
Revised in PubMed
2012-11-20
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Coenegrachts KKenneth
2Bols AAlain
3Haspeslagh MMarc
4Rigauts HHans

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CarcinomaMajor topic
Colorectal NeoplasmsMajor topic
Liver NeoplasmsMajor topic
Magnetic Resonance ImagingMajor topic
Aged
Aged, 80 and over
Contrast Media
Female
Humans
Male
Middle Aged
Prognosis
Reproducibility of Results
Sensitivity and Specificity
Treatment Outcome

Source PubMed

Download CSV of topics

Cited by14

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.

PMIDTitleJournalYearIn PapersSource
36688023Role of advanced imaging techniques in the evaluation of oncological therapies in patients with colorectal liver metastases.World J Gastroenterol2023https://conductscience.org/library/papers/36688023PubMed
33989042Quantitative magnetic resonance imaging for focal liver lesions: bridging the gap between research and clinical practice.Br J Radiol2021https://conductscience.org/library/papers/33989042PubMed
32514496Evaluation of liver tumour response by imaging.JHEP Rep2020https://conductscience.org/library/papers/32514496PubMed
31787860Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI.Contrast Media Mol Imaging2019https://conductscience.org/library/papers/31787860PubMed
31558870Colorectal cancer: Parametric evaluation of morphological, functional and molecular tomographic imaging.World J Gastroenterol2019https://conductscience.org/library/papers/31558870PubMed
30418878Discontinuity Preserving Liver MR Registration with 3D Active Contour Motion Segmentation.IEEE Trans Biomed Eng2018https://conductscience.org/library/papers/30418878PubMed
29922934Quantitative imaging features of pretreatment CT predict volumetric response to chemotherapy in patients with colorectal liver metastases.Eur Radiol2019https://conductscience.org/library/papers/29922934PubMed
28977973
Multiparametric imaging using 18F-FDG PET/CT heterogeneity parameters and functional MRI techniques: prognostic significance in patients with primary advanced oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy.
Oncotarget2017https://conductscience.org/library/papers/28977973PubMed
27187730Assessment of Aggressiveness of Breast Cancer Using Simultaneous 18F-FDG-PET and DCE-MRI: Preliminary Observation.Clin Nucl Med2016https://conductscience.org/library/papers/27187730PubMed
26911889Dynamic contrast-enhanced MRI, diffusion-weighted MRI and 18F-FDG PET/CT for the prediction of survival in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation.Eur Radiol2016https://conductscience.org/library/papers/26911889PubMed
26494642Potential of MR histogram analyses for prediction of response to chemotherapy in patients with colorectal hepatic metastases.Eur Radiol2016https://conductscience.org/library/papers/26494642PubMed
26078555Prognostication and response assessment in liver and pancreatic tumors: The new imaging.World J Gastroenterol2015https://conductscience.org/library/papers/26078555PubMed
23836505Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers.Mol Imaging Biol2014https://conductscience.org/library/papers/23836505PubMed
23732687Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence.Eur Radiol2013https://conductscience.org/library/papers/23732687PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/22944331

GET https://conductscience.org/api/papers/v1/22944331/authors